– SWITZERLAND, St Gallen – Vifor Pharma (SWX: VIFN) today announced changes to its management. Dr Klaus Henning Jensen will join the company as Chief Medical Officer and Member of the Executive Committee in January 2020. Dario Eklund, Chief Commercial Officer and member of the Executive Committee will leave the company at the end of September. A search for a successor is underway.
Stefan Schulze, President of Vifor Pharma Group Executive Committee and COO, comments; “We are delighted to announce the appointment of Dr Klaus Henning Jensen. Dr Jensen brings a wealth of experience from leading global clinical development and medical affairs functions at Sanofi and Novo Nordisk. We greatly look forward to welcoming him to the team in January. We would also like to thank Dario Eklund for his leadership and outstanding contributions to our success over the past 5 years. We wish him the very best for his future endeavors, both professionally and personally.”
Vifor Pharma also announces the departure of Dario Eklund. Dario Eklund joined Vifor Pharma in 2014 as Head of Global Business Operations, before becoming Chief Commercial Officer in 2017. He has decided to pursue opportunities outside of Vifor Pharma and will leave the organization by the end of September.
Dr Jensen joins Vifor Pharma from Sanofi, where he has most recently been Global Therapeutic Area Head, responsible for diabetes, cardiovascular and metabolism development. In his new role at Vifor Pharma, he will be responsible for Clinical Development, Drug Safety and Medical Affairs. He completed studies in Biophysics at the University of Copenhagen, and qualified as a Physician in 2003 and holds an Executive MBA from Copenhagen Business School.
About Vifor Pharma
Vifor Pharma Group is a global pharmaceuticals company headquartered in Switzerland. It aims to become the global leader in iron deficiency, nephrology and cardio-renal therapies. The company is the partner of choice for pharmaceuticals and innovative patient-focused solutions. Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, healthier lives. The company develops, manufactures and markets pharmaceutical products for precision patient care. Vifor Pharma Group holds a leading position in all its core business activities and consists of the following companies: Vifor Pharma; Vifor Fresenius Medical Care Renal Pharma; Relypsa; and OM Pharma. Vifor Pharma Group is listed on the Swiss Stock Exchange (SIX Swiss Exchange, VIFN, ISIN: CH0364749348).
For more information: http://www.viforpharma.com
- Disclaimer - News, data and statement included in this release are intended exclusively for general information purposes. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of the information. No data or statement in this release should be considered for decisions about securities referred. Product and brand names used in this release maybe trademarks or registered trademarks of their respective owners.
Comments are closed.